Berahyaluronidase alfa is a recombinant variant of human hyaluronidase PH20 that reversibly depolymerizes hyaluronan in subcutaneous tissue, increasing tissue permeability. It is combined with pembrolizumab in Keytruda Qlex for treating melanoma and non-small cell lung cancer. The enzyme enhances absorption of co-administered agents.
Summary written with AI from the sources listed at the end of this page.
Adjuvant treatment of Stage IIB, IIC, or III melanoma following complete resection
Metastatic nonsquamous NSCLC in combination with pemetrexed and platinum chemotherapy, first-line
Metastatic squamous NSCLC in combination with carboplatin and paclitaxel or paclitaxel protein-bound, first-line
NSCLC expressing PD-L1 (TPS ≥1%), Stage III or metastatic, first-line
Metastatic NSCLC expressing PD-L1 (TPS ≥1%) with disease progression on or after platinum-containing chemotherapy
Resectable NSCLC as neoadjuvant treatment in combination with platinum-containing chemotherapy
Adjuvant treatment of Stage IB, II, or IIIA NSCLC following resection and platinum-based chemotherapy
From the indications section of the FDA label (version of Jul 31, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.